Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Agustín Albillos, Aleksander Krag
For decades, non-selective beta-blockers (NSBBs) have been the standard of care for the primary and secondary prevention of bleeding from oesophageal varices. However, several questions regarding the best clinical use of NSBBs remain unanswered and new data continue to emerge. Herein, we aim to delineate the therapeutic window of NSBBs in cirrhosis from a more individualised perspective. We address the current controversy of widening the therapeutic window and prescribing NSBBs to all patients with clinically significant portal hypertension...
April 2023: Journal of Hepatology
#22
REVIEW
Joanna Forycka, Joanna Hajdys, Julia Krzemińska, Piotr Wilczopolski, Magdalena Wronka, Ewelina Młynarska, Jacek Rysz, Beata Franczyk
Empagliflozin is a relatively new drug that, as an inhibitor of the sodium−glucose cotransporter 2 (SGLT2), causes increased urinary glucose excretion and thus contributes to improved glycemic control, better glucose metabolism, reduced glucotoxicity and insulin resistance. Although its original use was to induce a hypoglycemic effect in patients with type 2 diabetes mellitus (T2DM), empagliflozin has also shown a number of other beneficial effects by demonstrating a nephroprotective effect, and it has proven to be a breakthrough in the treatment of heart failure (HF)...
December 19, 2022: Biomedicines
#23
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
November 2022: Kidney International
#24
REVIEW
Radica Z Alicic, Joshua J Neumiller, Rodolfo J Galindo, Katherine R Tuttle
Diabetes is the most common cause of kidney failure worldwide. Patients with diabetes and chronic kidney disease (CKD) are also at markedly higher risk of cardiovascular disease, particularly heart failure (HF), and death. Through the processes of gluconeogenesis and glucose reabsorption, the kidney plays a central role in glucose homeostasis. Insulin resistance is an early alteration observed in CKD, worsened by the frequent presence of hypertension, obesity, and ongoing chronic inflammation, and oxidative stress...
December 2022: KI Reports
#25
REVIEW
Ângelo Zambam de Mattos, Douglas Alano Simonetto, Carlos Terra, Alberto Queiroz Farias, Paulo Lisboa Bittencourt, Tales Henrique Soares Pase, Marlon Rubini Toazza, Angelo Alves de Mattos
Mortality in cirrhosis is mostly associated with the development of clinical decompensation, characterized by ascites, hepatic encephalopathy, variceal bleeding, or jaundice. Therefore, it is important to prevent and manage such complications. Traditionally, the pathophysiology of decompensated cirrhosis was explained by the peripheral arterial vasodilation hypothesis, but it is currently understood that decompensation might also be driven by a systemic inflammatory state (the systemic inflammation hypothesis)...
September 7, 2022: World Journal of Gastroenterology: WJG
#26
JOURNAL ARTICLE
Ian M Gralnek, Marine Camus Duboc, Juan Carlos Garcia-Pagan, Lorenzo Fuccio, John Gásdal Karstensen, Tomas Hucl, Ivan Jovanovic, Halim Awadie, Virginia Hernandez-Gea, Marcel Tantau, Alanna Ebigbo, Mostafa Ibrahim, Jiannis Vlachogiannakos, Marc C Burgmans, Robyn Rosasco, Konstantinos Triantafyllou
1: ESGE recommends that patients with compensated advanced chronic liver disease (ACLD; due to viruses, alcohol, and/or nonobese [BMI < 30 kg/m2 ] nonalcoholic steatohepatitis) and clinically significant portal hypertension (hepatic venous pressure gradient [HVPG] > 10 mmHg and/or liver stiffness by transient elastography > 25 kPa) should receive, if no contraindications, nonselective beta blocker (NSBB) therapy (preferably carvedilol) to prevent the development of variceal bleeding...
November 2022: Endoscopy
#27
REVIEW
Patrick B Mark, Kenneth Mangion, Alastair J Rankin, Elaine Rutherford, Ninian N Lang, Mark C Petrie, Sokratis Stoumpos, Rajan K Patel
Chronic kidney disease (CKD) is a risk factor for premature cardiovascular disease. As kidney function declines, the presence of left ventricular abnormalities increases such that by the time kidney replacement therapy is required with dialysis or kidney transplantation, more than two-thirds of patients have left ventricular hypertrophy. Historically, much research in nephrology has focussed on the structural and functional aspects of cardiac disease in CKD, particularly using echocardiography to describe these abnormalities...
December 2022: Clinical Kidney Journal
#28
JOURNAL ARTICLE
Josef S Smolen, Robert B M Landewé, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher John Edwards, Kimme L Hyrich, Janet E Pope, Savia de Souza, Tanja A Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin L Winthrop, Alejandro Balsa, Joan M Bathon, Maya H Buch, Gerd R Burmester, Frank Buttgereit, Mario Humberto Cardiel, Katerina Chatzidionysiou, Catalin Codreanu, Maurizio Cutolo, Alfons A den Broeder, Khadija El Aoufy, Axel Finckh, João Eurico Fonseca, Jacques-Eric Gottenberg, Espen A Haavardsholm, Annamaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B McInnes, Eduardo F Mysler, Peter Nash, Gyula Poor, Gorica G Ristic, Felice Rivellese, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Nikolay Stoilov, Anja Strangfeld, Annette van der Helm-van Mil, Elsa van Duuren, Theodora P M Vliet Vlieland, René Westhovens, Désirée van der Heijde
OBJECTIVES: To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field. METHODS: An international task force was formed and solicited three systematic literature research activities on safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs). The new evidence was discussed in light of the last update from 2019. A predefined voting process was applied to each overarching principle and recommendation...
January 2023: Annals of the Rheumatic Diseases
#29
REVIEW
Koshi Hashimoto
Subclinical thyroid dysfunction is defined by serum thyroid-stimulating hormone (TSH) levels either greater or less than the reference range with normal thyroxine (T4) concentrations, and consists of subclinical hypothyroidism (SCH) and subclinical hyperthyroidism (SCHyper). For the proper diagnosis of SCH, it is most important to be able to correctly evaluate the serum TSH levels, which have numerous unique characteristics. We also need to be versed in TSH harmonization, which was recently launched world-wide...
July 28, 2022: Endocrine Journal
#30
RANDOMIZED CONTROLLED TRIAL
William G Herrington, Natalie Staplin, Christoph Wanner, Jennifer B Green, Sibylle J Hauske, Jonathan R Emberson, David Preiss, Parminder Judge, Kaitlin J Mayne, Sarah Y A Ng, Emily Sammons, Doreen Zhu, Michael Hill, Will Stevens, Karl Wallendszus, Susanne Brenner, Alfred K Cheung, Zhi-Hong Liu, Jing Li, Lai Seong Hooi, Wen Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Cherney, Aldo P Maggioni, Roberto Pontremoli, Rajat Deo, Shinya Goto, Xavier Rossello, Katherine R Tuttle, Dominik Steubl, Michaela Petrini, Dan Massey, Jens Eilbracht, Martina Brueckmann, Martin J Landray, Colin Baigent, Richard Haynes
BACKGROUND: The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. METHODS: We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m2 of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1...
January 12, 2023: New England Journal of Medicine
#31
REVIEW
Viswanathan Mohan, Awadhesh Kumar Singh, Abdul Hamid Zargar, Alan Almeida, Anil Kumar Bhalla, Jagadish Chander Mohan, Jamshed Dalal, Manisha Sahay, Padhinhare P Mohanan, Sanjay Maitra, Sujoy Ghosh, Tarun Jeloka, Upendra Kaul, Vinay Sakhuja, Mrinal Kanti Das
BACKGROUND AND AIM: The interplay between cardiovascular disease (CVD), chronic kidney disease (CKD) and type 2 diabetes (T2D) is well established. We aim at providing an evidence-based expert opinion regarding the prevention and treatment of both heart failure (HF) and renal complications in people with T2D. METHOD: ology: The consensus recommendations were developed by subject experts in endocrinology, cardiology, and nephrology. The criteria for consensus were set to statements with ≥80% of agreement among clinicians specialized in endocrinology, cardiology, and nephrology...
December 2022: Diabetes & Metabolic Syndrome
#32
REVIEW
Kevin Mortimer, Helen K Reddel, Paulo M Pitrez, Eric D Bateman
Asthma is the most common noncommunicable disease in children, and among the most common in adults. The great majority of people with asthma live in low and middle income countries (LMICs), which have disproportionately high asthma-related morbidity and mortality. Essential inhaled medications, particularly those containing inhaled corticosteroids (ICS), are often unavailable or unaffordable, and this explains much of the global burden of preventable asthma morbidity and mortality. Guidelines developed for LMICs are generally based on the outdated assumption that patients with asthma symptoms <1-3 times per week do not need (or benefit from) ICS...
September 2022: European Respiratory Journal
#33
REVIEW
Andrea Crosignani, Stefano Spina, Francesco Marrazzo, Stefania Cimbanassi, Manu L N G Malbrain, Niels Van Regenmortel, Roberto Fumagalli, Thomas Langer
Patients with acute pancreatitis (AP) often require ICU admission, especially when signs of multiorgan failure are present, a condition that defines AP as severe. This disease is characterized by a massive pancreatic release of pro-inflammatory cytokines that causes a systemic inflammatory response syndrome and a profound intravascular fluid loss. This leads to a mixed hypovolemic and distributive shock and ultimately to multiorgan failure. Aggressive fluid resuscitation is traditionally considered the mainstay treatment of AP...
October 17, 2022: Annals of Intensive Care
#34
REVIEW
Samar Alharbi
Systemic lupus erythematosus (SLE) is an autoimmune disorder of unknown etiology. Women of childbearing age are affected approximately nine times more often than men. Its presentation and course are highly variable, ranging from mild to fulminant systemic disease. Any organ can be affected by SLE. Although less common than in other systems, such as the skin, joints, and kidneys, 40%-60% of SLE patients have gastrointestinal (GI) involvement. SLE can affect any part of the GI tract, from the mouth to the anus...
2022: Open Access Rheumatology: Research and Reviews
#35
REVIEW
Scott Williams, Siddig Abdel Raheim, Muhammad Ilyas Khan, Umme Rubab, Prathap Kanagala, Sizheng Steven Zhao, Anne Marshall, Emily Brown, Uazman Alam
PURPOSE: Cardiac autonomic neuropathy (CAN) is a serious complication of type 1 and type 2 diabetes and is independently associated with major cardiovascular events, morbidity, and mortality. This narrative review examines the epidemiology, pathophysiology, and management and identifies areas of future research to address the challenge posed by CAN. METHODS: We conducted a comprehensive literature search using a range of sources, including the electronic databases PubMed Central, Google Scholar, OVID, and Open Athens, to search for studies on CAN, diabetes mellitus, lifestyle intervention, and cardiovascular risk...
October 2022: Clinical Therapeutics
#36
REVIEW
Roko Skrabic, Marko Kumric, Josip Vrdoljak, Doris Rusic, Ivna Skrabic, Marino Vilovic, Dinko Martinovic, Vid Duplancic, Tina Ticinovic Kurir, Josko Bozic
In recent years, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have demonstrated beneficial renoprotective effects, which culminated in the recent approval of their use for patients with chronic kidney disease (CKD), following a similar path to one they had already crossed due to their cardioprotective effects, meaning that SGLT2i represent a cornerstone of heart failure therapy. In the present review, we aimed to discuss the pathophysiological mechanisms operating in CKD that are targeted with SGLT2i, either directly or indirectly...
October 1, 2022: Biomedicines
#37
JOURNAL ARTICLE
Bruno A M P Besen, Otavio T Ranzani, Mervyn Singer
No abstract text is available yet for this article.
January 2023: Intensive Care Medicine
#38
REVIEW
Thomas Forst, Chantal Mathieu, Francesco Giorgino, David C Wheeler, Nikolaos Papanas, Roland E Schmieder, Atef Halabi, Oliver Schnell, Marina Streckbein, Katherine R Tuttle
BACKGROUND: Diabetic kidney disease (DKD), the most common cause of kidney failure and end-stage kidney disease worldwide, will develop in almost half of all people with type 2 diabetes. With the incidence of type 2 diabetes continuing to increase, early detection and management of DKD is of great clinical importance. MAIN BODY: This review provides a comprehensive clinical update for DKD in people with type 2 diabetes, with a special focus on new treatment modalities...
October 10, 2022: BMC Medicine
#39
JOURNAL ARTICLE
Li-Li Tong, Sharon G Adler
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease and end-stage kidney disease worldwide, as the obesity epidemic and the burden of diabetes continue to rise globally. In general, guideline management of patients with DKD recommends lifestyle modifications, blood pressure and glycemic control, and dyslipidemia treatment along with other cardiovascular disease risk reduction measures. The inhibition of the renin-angiotensin system (RAS) using an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker remains the foundational therapy for DKD...
September 2022: Kidney Research and Clinical Practice
#40
REVIEW
Melanie J Davies, Vanita R Aroda, Billy S Collins, Robert A Gabbay, Jennifer Green, Nisa M Maruthur, Sylvia E Rosas, Stefano Del Prato, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Tsvetalina Tankova, Apostolos Tsapas, John B Buse
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycaemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional healthcare team providing diabetes care in the USA and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the healthcare system and physical activity behaviours including sleep...
December 2022: Diabetologia
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
